KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Gross Margin (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Gross Margin data on record, last reported at 42.91% in Q4 2025.

  • For Q4 2025, Gross Margin rose 351.0% year-over-year to 42.91%; the TTM value through Dec 2025 reached 56.09%, up 797.0%, while the annual FY2025 figure was 56.09%, 2137.0% up from the prior year.
  • Gross Margin reached 42.91% in Q4 2025 per EBS's latest filing, down from 62.83% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.95% in Q1 2021 and bottomed at 6.94% in Q1 2023.
  • Average Gross Margin over 5 years is 56.52%, with a median of 52.52% recorded in 2025.
  • Peak YoY movement for Gross Margin: surged 5656bps in 2022, then tumbled -6672bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 39.9% in 2021, then surged by 142bps to 96.46% in 2022, then crashed by -66bps to 33.08% in 2023, then increased by 19bps to 39.39% in 2024, then increased by 9bps to 42.91% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 42.91% in Q4 2025, 62.83% in Q3 2025, and 52.52% in Q2 2025.